Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
08:12am, Sunday, 14'th Jan 2024
The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
02:20pm, Friday, 29'th Dec 2023
ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted
ADC Therapeutics: Navigating A Swirling Drain
05:42pm, Friday, 01'st Dec 2023
ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the r
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Tuesday, 07'th Nov 2023
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.65 per share a year ago.
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:17am, Tuesday, 31'st Oct 2023
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
07:00am, Tuesday, 24'th Oct 2023
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m.
ADC Therapeutics to Participate in September Investor Conferences
07:00am, Tuesday, 05'th Sep 2023
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in S
ADC Therapeutics: Slowly Moving Toward Solvency
07:15pm, Tuesday, 29'th Aug 2023
ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
09:56am, Tuesday, 08'th Aug 2023
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.73 per share a year ago.
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
07:00am, Tuesday, 01'st Aug 2023
LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. E
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
02:28pm, Friday, 21'st Jul 2023
We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:09am, Friday, 14'th Jul 2023
ADC Therapeutics SA (ADCT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement
After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)
11:08am, Thursday, 13'th Jul 2023
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study
11:49am, Wednesday, 12'th Jul 2023
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are u
ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy
07:28am, Tuesday, 11'th Jul 2023
ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concern
